Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Edwards Lifesciences Corp (EW)

Edwards Lifesciences Corp (EW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,391,216
  • Shares Outstanding, K 580,300
  • Annual Sales, $ 5,440 M
  • Annual Income, $ 4,175 M
  • EBIT $ 1,385 M
  • EBITDA $ 1,540 M
  • 60-Month Beta 1.03
  • Price/Sales 8.79
  • Price/Cash Flow 30.19
  • Price/Book 4.74

Options Overview Details

View History
  • Implied Volatility 23.89% ( -0.22%)
  • Historical Volatility 24.27%
  • IV Percentile 20%
  • IV Rank 16.96%
  • IV High 52.16% on 04/08/25
  • IV Low 18.11% on 08/28/25
  • Put/Call Vol Ratio 0.44
  • Today's Volume 4,690
  • Volume Avg (30-Day) 5,553
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 126,631
  • Open Int (30-Day) 110,233

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.61
  • Number of Estimates 12
  • High Estimate 0.63
  • Low Estimate 0.59
  • Prior Year 0.59
  • Growth Rate Est. (year over year) +3.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
72.30 +15.34%
on 10/13/25
87.09 -4.25%
on 10/31/25
+6.67 (+8.69%)
since 10/07/25
3-Month
72.30 +15.34%
on 10/13/25
87.09 -4.25%
on 10/31/25
+5.46 (+7.01%)
since 08/07/25
52-Week
64.89 +28.51%
on 11/12/24
87.09 -4.25%
on 10/31/25
+17.55 (+26.66%)
since 11/07/24

Most Recent Stories

More News
Edwards Champions American Heart Association Initiative to Reduce Deaths, Improve Care for Patients With Heart Valve Disease

Edwards Lifesciences (NYSE: EW) today announced its founding sponsorship of the American Heart Association’s Heart Valve Initiative, a national effort to improve care and outcomes for the more than 28...

EW : 83.39 (+1.15%)
Edwards Lifesciences Announces CFO Transition Plan

Edwards Lifesciences (NYSE: EW) today announced that Scott Ullem, the company’s chief financial officer, has decided to transition from his role by midyear 2026. While the company initiates a selection...

EW : 83.39 (+1.15%)
Edwards Lifesciences Reports Third Quarter Results

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2025. Recent Highlights ...

EW : 83.39 (+1.15%)
Halper Sadeh LLC Encourages Edwards Lifesciences Corporation Shareholders to Contact the Firm to Discuss Their Rights

Shareholders should contact the firm immediately as there may be limited time to enforce your rights.

EW : 83.39 (+1.15%)
Successful Patient Outcomes Demonstrated With Edwards’ SAPIEN M3 and EVOQUE Systems, New Data Presented at TCT 2025

ENCIRCLE mitral trial achieves primary and secondary endpoints EVOQUE tricuspid valve registry demonstrates more favorable outcomes than pivotal trial

EW : 83.39 (+1.15%)
Edwards SAPIEN 3 TAVR Delivers Proven Long-term Benefits and Valve Performance, New Data Presented at TCT 2025

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years

EW : 83.39 (+1.15%)
Edwards Lifesciences to Host Earnings Conference Call on October 30, 2025

Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended September 30, 2025 after the market closes on Thursday October 30, 2025, and will host a conference call at...

EW : 83.39 (+1.15%)
Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation - EW

NEW YORK , Oct. 22, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Edwards...

EW : 83.39 (+1.15%)
Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX) and Edwards Lifesciences (EW)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GoodRx Holdings (GDRX – Research Report) and Edwards Lifesciences (EW – Research Report).Elevate Your Investing Strategy:...

EW : 83.39 (+1.15%)
GDRX : 3.11 (-1.58%)
EW Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Edwards Lifesciences Corporation – EW

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential breaches of fiduciary duties by the directors and officers of Edwards Lifesciences Corporation (NYSE: EW). ...

EW : 83.39 (+1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair...

See More

Key Turning Points

3rd Resistance Point 85.61
2nd Resistance Point 84.72
1st Resistance Point 84.05
Last Price 83.39
1st Support Level 82.49
2nd Support Level 81.60
3rd Support Level 80.93

See More

52-Week High 87.09
Last Price 83.39
Fibonacci 61.8% 78.61
Fibonacci 50% 75.99
Fibonacci 38.2% 73.37
52-Week Low 64.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar